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Abstract: While there is some evidence that migration to Western countries increases metabolic
syndrome (MetS) risk, there is a lack of data pertaining to migration to the Middle East. This study
aimed to investigate the relationship between migration and MetS incidence following 24-months of
residency in Qatar and identify possible MetS determinants. Migrants to Qatar employed at Hamad
Medical Corporation (the national health service) aged 18–65 years were invited to participate.
Baseline and follow-up screening for MetS included HbA1c, triglycerides, HDL-cholesterol, blood
pressure, and waist circumference. MetS-free migrants were rescreened 24-months post-migration,
and the World Health Organization STEPwise questionnaire was administered, assessing changes
in lifestyle from baseline. Of 1095 migrants contacted, 472 consented to participate, 205 of whom
had normal metabolic parameters at baseline; 160 completed follow-up screening. Most participants
were males (74.6%, n = 153) and Asian (81.0%, n = 166/205), and two thirds (66.3%, n = 136/205)
were nurses. The incidence of new-onset MetS was 17.0% (n = 27/160, 95%CI; 11.0–23.0%), with
81.0% (n = 129/160, 95%CI; 73.8–86.0%) having at least one MetS element 24-months post-residency
in Qatar. Male gender was a risk factor for MetS (adjusted odds ratio (AOR) = 3, p = 0.116), as was
consuming medication that could induce MetS (AOR = 6.3, p < 0.001). There is merit in further
research targeting these groups.
Keywords: metabolic syndrome; migration; incidence; determinants; Qatar
1. Introduction
The American Heart Association considers metabolic syndrome (MetS) a global epi-
demic [1,2], affecting around one-quarter of people worldwide and being a significant cause
of morbidity and mortality [3,4]. While the syndrome consists of commonly occurring
chronic diseases including diabetes mellitus (DM), hypertension (HTN), dyslipidemia, and
obesity, it is underdiagnosed by physicians [2,5].
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In 2009, the International Diabetes Federation (IDF) task force published the Consensus
Worldwide Definition of MetS. Any three of the following five elements are sufficient
to diagnose MetS; HTN, DM, elevated triglycerides (TG), low high-density lipoprotein
cholesterol (HDL-C), or central obesity (Table 1) [6]. In the past decade, the IDF MetS
criteria have been the most widely quoted in the literature [7–12], and consequently were
adopted throughout this research.
Table 1. Updated criteria for clinical diagnosis of Metabolic Syndrome [6].
Measure Categorical Cut Points
Patients were diagnosed as having MetS if they had any three out of the following five elements:
Elevated TG ≥1.7 mmol/L, or drug treatment for elevated triglycerides
Reduced HDL-C <1.0 mmol/L in males, <1.3 mmol/L in females, or drug treatment for reduced HDL-C
Elevated BP Systolic ≥130 and/or diastolic ≥85 mmHg, or on antihypertensive drug treatment
Elevated FBG ≥5.5 mmol/L, or drug treatment for high glucose
Elevated WC Country/ethnic group waist circumference (a measure of central obesity) [3]
Europids: Male ≥ 94 cm, Female ≥ 80 cm
South Asians: Male ≥ 90 cm, Female ≥ 80 cm
Chinese: Male ≥ 90 cm, Female ≥ 80 cm
Japanese: Male ≥ 90 cm, Female ≥ 85 cm
Ethnic South and Central Americans: Use South Asian recommendations until more specific data are
available.
Sub-Saharan Africans: Use European data until more specific data are available.
Eastern Mediterranean and Middle East (Arab) populations: Use European data until more specific data are
available.
TG; triglycerides; HDL-C, high-density lipoprotein cholesterol, BP; blood pressure; FBG, fasting blood glucose;
WC, waist circumference.
In addition to modifiable clinical elements, other factors have been linked to an
increased risk of MetS development, including psychological factors of anger, stress, anxiety,
and sleep deprivation. [13,14]. Moreover, accumulating evidence has linked migration to
MetS and its elements of DM, HTN, dyslipidemia, and central obesity [15–20].
The process by which migration increase the risk of MetS is multifactorial, with precip-
itating factors including urbanisation [21,22], Westernisation [23–28], reduced leisure-time
physical activity [29], acculturation and acculturation stress [30–35], and the migration pe-
riod. The time spent by migrants away from their original home country before developing
MetS or any of its core elements is uncertain. Ranges reported in the literature are between
1 and more than 15 years [15,17,30,36–40].
MetS is particularly relevant to the Middle East, with evidence of a high rate of non-
communicable diseases amongst migrants to the region. A recent cross-sectional study
reported a high prevalence of MetS amongst migrants to Qatar of 48.8% [41]. Moreover, a
recent scoping review gave a prevalence of HTN of 30.5%, DM of 9.0–16.0%, and pre-DM of
30.5% amongst South Asian migrants (India, Bangladesh, and Pakistan) [42]. While three
studies have assessed MetS prevalence amongst the native Qatar population [41,43,44],
only one included migrants, but it did not focus on potential determinants [41].
The aim of this study was to investigate the relationship between migration and
the incidence of MetS following 24-month residency in Qatar and to identify possible
MetS determinants.
2. Materials and Methods
2.1. Setting
This study was conducted within the Hamad Medical Corporation (the HMC), the na-
tional health service provider in Qatar, which comprises 20 facilities. More than 25,000 em-
ployees of considerable ethnic diversity work in the HMC, with employees having migrated
from more than 90 countries [45].
J. Clin. Med. 2022, 11, 34 3 of 15
2.2. Study Design
This study had a prospective, longitudinal, observational design with a nested cross-
sectional survey. It was conducted in two phases: the first involved baseline screening of
migrants within three months of arrival to Qatar (1 July to 31 December 2017). The second
phase was a prospective follow-up of those with normal metabolic parameters at baseline
at 24-months post-migration. A summary of the recruitment and research processes is
shown in Figure 1.
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2.3. a le ize
iter t r t r t st igrants range from 17.0–39.0%, with the majority
of studies reporting 20.0–30.0% [46–50]. Using an estimated rate of 25.0 ± 5%, the study
sample size was calculated to be 289 participants, with a precision of 5.0% and 95.0%
CIs [51].
2.4. Study Participants and Recruitment
The study population comprised migrants employed at HMC, where all new employ-
ees are subjected to a pre-employment medical examination. Participants were included
if they were new migrants and had joined HMC during the 6-month recruitment period
(July–December 2017) and were aged 16–65 years. Participants were excluded if they
were pregnant females or former citizens in Qatar or the Gulf region, due to cultural and
economic similarities between the Gulf countries.
Phase 1 (screening): Following ethical approval, the pre-employment staff clinic
provided contact details for those who joined HMC from 1 July to 31 December 2017.
Participants who fulfilled the inclusion criteria were contacted via telephone and provided
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with brief study information. If interested, an appointment was booked at which further
information was provided and written consent obtained.
Phase 2 (follow-up): Study participants were those identified as MetS-free at Phase 1.
Those identified as having MetS or any MetS elements at Phases 1 or 2 were referred for
appropriate management and follow-up.
2.5. Data Collection Tools and Data Collection
A data collection tool was developed to address the research objectives, and was
piloted among 10 participants to ensure accuracy and comprehensiveness. The pilot
data was excluded from the main study. The following data were extracted from the
electronic medical records at baseline and follow-up: socio-demographic information,
physical measurements, and biochemical measurements of blood glucose and lipid profiles
(TG and HDL-C). Data collection was repeated in a 50% random sample by a second
researcher to confirm reliability.
At follow-up, participants were contacted to remind them to attend any HMC lab-
oratory, and to book an appointment to complete the WHO STEPwise questionnaire.
Laboratory results were extracted from electronic medical profiles, and reliability was again
confirmed. The follow-up laboratory tests were fasting TG, fasting blood glucose (FBG),
HDL-C, and HbA1c.
The WHO STEPwise characterised any changes in lifestyle as part of the migration
process. This validated questionnaire was developed to aid the surveillance of risk factor
trends within and between countries [52] and comprises eleven core domains. Participants
were requested to answer each question relating to lifestyle habits at baseline and 24-months
post-migration.
2.6. Data Handling and Analysis
Data were entered into Microsoft Excel® (Microsoft Corporation, 2018) then exported
to SPSS® Version 26 (IBM Corp. Released 2015. IBM statistical analysis for Windows
Version 26. Armonk, NY: USA IBM Corp). The Kolmogorov–Smirnov test determined the
normality of continuous data. The incidence of new MetS-development and each element
were determined by Incidence rate = (Number of new MetS cases or elements)/Number of
participants who completed the follow-up) × 100 [53]. Differences in means of normally
distributed data from baseline to follow-up were tested using the paired sample t-test.
The Wilcoxon Signed Rank test was used for non-normally distributed data. Associations
between the incidence of MetS or the elements (1 or 2 elements) with the categorical
parameters and the non-normally distributed continuous parameters were tested using the
Pearson Chi-square test. Associations with the normally distributed parameters were tested
using one-way ANOVA. Significant variables from the univariate analysis were utilised to
construct the multiple univariate logistic regression model to determine any association
with MetS incidence. All p-values presented were two-tailed, and p-values < 0.05 were
considered statistically significant.
2.7. Research Ethics
The study was approved by the School of Pharmacy and Life Sciences ethics committee
at Robert Gordon University (RGU) and the Institutional Review Board (IRB) of the Medical
Research Center at the HMC in Qatar [RGU S97; HMC-IRB Registration: SCH-HMC-020-
2015]. Written consent was obtained from all participants.
3. Results
During the study period, 1379 employees joined the HMC, of whom 1084 were con-
tacted (Figure 2). Following access to individual electronic medical profiles, 205 participants
were identified as having no element of MetS and were included in the follow-up. Seven
participants became pregnant and were excluded from follow-up, and 38 only partially
completed the laboratory follow-up (Figure 2).
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came from Asia. The majority were healthcare providers, predominantly nurses (n= 136, 
66.3%; Table 2). 
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Of the 205 eligible participants, 196 (95.6%) completed the STEPwise questionnaire
24-months post-residency in Qatar. Most were non-smokers (n = 181, 92.3%) and met the
WHO criteria for physical activity (n = 183, 93.4%). The lifestyle parameters at baseline
and 24-months post-migration are given in Table 3. The mean times spent in vigorous and
moderate activities at follow-up dropped by 50% compared to baseline (p = 0.001 for both,
Wilcoxon Signed Rank test). The reduced moderate and vigorous physical activity levels
at follow-up were not associated with MetS incidence (p = 0.792, p = 0.680 respectively,
Pearson Chi-Square test).
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Table 2. Characteristics of the MetS-free participants (n = 205) at baseline within 3 months of arrival
to Qatar in 2017.
Characteristic Values % (n)















Below bachelor’s degree 1.5% (3)
Graduate (Bachelor & Diploma) 77.0% (158)




Allied healthcare 15.1% (31)
Others ** 4.9% (10)
WHO, World Health Organisation. ¥ ± represents standard deviation (SD) of the mean. * Others included: North
Americans, South Americans, Australians–Oceanians. ** Other occupations included: clerk, engineer, IT and
aides. Median and IQ range reported due to data skewness.
Table 3. Lifestyle parameters at baseline and 24-months post-migration (n = 196).
Lifestyle Parameters Baseline % (n) 24-MonthsPost-Migration % (n)
Smokers
Yes 2.1% (4) 11.2% (22)
No 92.3% (181) 88.8% (174)
Missing 5.6% (11) 0
Alcohol consumers
Yes 41.8% (82)
No NA 58.2% (114)
Mean (SD) number of days fruit consumed in a week (days/week) 3.8 ± 2.3 days/week ¥ 4.4 ± 2.3 days/week ¥
Mean (SD) number of servings of fruit consumed on average per day 1.32 ± 0.7 serves/day ¥ 1.25 ± 0.6 serves/day ¥
Mean (SD) number of days vegetables consumed in a week (days/week) 4.7 ± 2.2 days/week ¥ 4 ± 2.3 days/week ¥
Mean (SD) number of servings of vegetables consumed on average per day 1.6 ± 0.7 serves/day ¥ 1.35 ± 0.6 serves/day ¥
Median (IQR) number of mins of moderate activities per week 1800 (540–2850) min ¶ 1410 (418–2400) min ¶
Median (IQR) number of mins of vigorous activities week 120 (0–300) min ¶ 60 (0–240) min
Met WHO criteria for moderate activity
Yes 89.3% (175) 84.7% (166)
No 9.2% (18) 15.3% (30)
Missing 1.5% (3) 0
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Table 3. Cont.
Lifestyle Parameters Baseline % (n) 24-MonthsPost-Migration % (n)
Met WHO criteria for vigorous activity
Yes 54.6% (107) 43.9% (86)
No 42.3% (83) 51.0% (100)
Missing 3.1% (6) 5.1% (10)
Met the WHO criteria for physical activity (vigorous or moderate)
Yes 93.4% (183) 91.3% (179)
No 6.6% (13) 8.7% (17)
Met WHO recommendations for diet baseline
Yes 5.1% (10) 2.5% (5)
No 94.9% (186) 97.5% (191)
¥ ± represents standard deviation (SD) of the mean. ¶ Median and IQ range reported due to data skewness.
At follow-up, 160 of 205 participants completed all the requested laboratory workup
(the five elements of MetS). The incidence of new-onset MetS during the 24 months of
residing in Qatar was 17.0% (n = 27/160, 95% CI; 11.0–23.0%); 81.0% (n = 129/160) of
participants developed at least one element of MetS (Table 4). Only 19.0% (31/160) of
participants were still MetS free 24-months post-migration.
Table 4. Incidence of MetS and MetS elements 24-months post-migration.
Metabolic/Parameters Values % (n) 95% CI
Zero elements of MetS (n = 160) ¥ 19.0% (31) 14.0–26.0%
One element of MetS (n = 160) ¥ 33.0% (52) 25.0–40.0%
Two elements of MetS (n = 160) ¥ 31.0% (50) 24.0–39.0%
Three or more elements of MetS (n = 160) ¥ 17.0% (27) 11.0–23.0%
HTN
SBP ≥ 130 mmHg (n = 197) ¥ 19.3% (38) 14.0–26.0%
DBP ≥ 85 mmHg (n = 197) ¥ 13.7% (27) 9.0–19.0%
SBP ≥ 130 mmHg or DBP ≥ 85 mmHg or on antihypertensive medications (n = 197) ¥ 33.0% (65) 27.0–40.0%
DM, pre-DM
FBG > 5.5 mmol/L or on medications (n = 169) ¥ 26.6% (45) 20.0–34.0%
FBG > 5.5 mmol/L or HbA1c > 5.6% or on medications (n = 167) ¥ 33.5% (56) 26.0–41.0%
FBG > 5.5 mmol/L or HbA1c > 6.5% or on medications (n = 167) ¥ 3.6% (6) 1.0–8.0%
Dyslipidaemia
TG ≥ 1.7 mmol/L (n = 166) ¥ 18.7% (31) 13.0–26.0%
HDL-C < 1.03 mmol/L for males or <1.29 mmol/L for females (n = 165) ¥ 9.7% (16) 6.0–15.0%
HDL-C < 1.03 mmol/L for males or <1.29 mmol/L for females or TG ≥ 1.7 mmol/L or on
medications (n = 166) ¥ 30.7% (51) 22.0–37.0%
Obesity
WC ≥ 90 cm for male and ≥80 cm for females * (n = 191) ¥ 56.5% (108) 49.0–64.0%
WC above the range * or on anti-obesity medications (n = 192) ¥ 56.8% (109) 49.0–64.0%
MetS, metabolic syndrome; HTN, hypertension; SBP, systolic blood pressure; DBP, diastolic blood pressure;
DM, diabetes mellitus; FBG, fasting blood glucose; HbA1c, glycated haemoglobin; TG; triglycerides; HDL-C,
high-density lipoprotein cholesterol; WC, waist circumference. * WC ≥ 90 cm for males and ≥80 cm for females,
except for Europid males ≥ 95 cm and Japanese females ≥ 85 cm—please refer to Table 1. ¥ The number of the
participants vary between the parameters, due to missing data. Thirty-eight partially completed the laboratory
workup, while 160 completed it all.
As shown in Table 4, at follow-up more than half of the participants developed
central obesity (56.5%, n = 108/191, 95% CI; 49.0–64.0%), 33.5% (n = 56/167, 95% CI;
26.0–41.0%) developed elevated glycaemic parameters (either abnormal FBG, HbA1c or on
DM medications), while 33.0% (n = 65/197, 95% CI; 27.0–40.0%) developed HTN (elevated
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SBP, and DBP, or on antihypertensive medications), and 18.7% (n = 31/166, CI; 13.0–26.0%)
had new-onset hypertriglyceridemia.
All metabolic parameters were statistically significantly raised at follow-up compared
to baseline, with the exception of SBP (Table 5). FBG values were not compared because
these were not available for all participants at baseline.
Table 5. Comparison of metabolic parameters at baseline and follow-up.
Metabolic Parameter Baseline (2017) ¥ Follow-Up (2019) ¥ t-Value ¶ df p-Value *
SBP mmHg (n = 196) 119 ± 9.3 120 ± 12.0 −1.73 195 0.085
DBP mmHg (n = 197) 71 ± 9.0 75 ± 10.0 −4.90 196 <0.001
HbA1c % (n = 166) 5.1 ± 0.3 5.4 ± 0.3 −13.90 165 <0.001
TG mg/dL (n = 166) 1 ± 0.4 1.2 ± 0.7 −4.56 165 <0.001
HDL-C mg/dL (n = 165) 1.29 ± 0.3 1.34 ± 0.3 −3.15 164 0.002
WC cm (n = 192) 84.2 ± 5.5 88.4 ± 6.9 −12.05 191 <0.001
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, glycated haemoglobin; TG,
triglycerides; HDL-C, high-density lipoprotein cholesterol. ¥ ± represents standard deviation (SD) of the mean.
¶ Paired Sample t-test test-value. * Paired Sample t-test.
There was a significant association between male gender and developing MetS (Chi-
square = 13.4, df = 4, p = 0.01). Additionally, administration of medications that potentially
induce MetS was significantly associated with an increased risk of MetS or its elements
(Chi-square = 16.9, df = 4, p = 0.002) compared to those not taking such medications
(Table 6). Age was not compared as most participants were of a similar age (mean age
31.2 + 5.2 years). Ethnic groups, marital status, education, occupation, diet, and exercise
had no statistically significant effect on incidence of new-onset MetS. Of note, no patients
were identified as having five elements of MetS at the end of the 24 months.
Table 6. Comparison of migrants with one, two, three and four elements of MetS and MetS-free
migrants 24 months post-migration to Qatar regarding variables of demographics and the modifiable


















Male 64.5% (20) 73.1% (38) 86.0% (43) 100% (18) 55.6% (5)
Female 35.5% (11) 26.9% (14) 14.0% (7) 0 44.4% (4) 13.4 4 0.01 *
Ethnic group
Arabs 6.5% (2) 7.7% (4) 10.0% (5) 5.6% (1) 0
Asians 90.3% (28) 78.8% (41) 74.0% (37) 94.4% (17) 88.9% (8)
Africans 0 1.9% (1) 6.0% (3) 0 0
European 0 5.8% (3) 4.0% (2) 0 0
Others † 3.2% (1) 5.8% (3) 6.0% (3) 0 11.1% (1) 11.3 16 0.788 *
Marital status
Married 22.6% (7) 48.1% (25) 50.0% (25) 61.1% (11) 55.6% (5)
Single 71.0% (22) 50.0% (26) 50.0% (25) 38.9% (7) 44.4% (4)
Divorced 6.4% (2) 1.9% (1) 0 0 0 10.2 8 0.254 *
Education
Below Bachelor’s degree 6.4% (2) 0 0 0 0
Graduate (Bachelor, Diploma) 83.9% (26) 80.8% (42) 72.0% (36) 77.8% (14) 66.7% (6)
Postgraduate (Master and above) 9.7% (3) 19.2% (10) 28.0% (14) 22.2% (4) 33.3% (3) 12.7 8 0.123 *
Occupation
Doctors 6.5% (2) 11.5% (6) 12.0% (6) 11.1% (2) 22.2% (2)
Nurses 70.9% (22) 71.2% (37) 58.0% (29) 83.3% (15) 66.7% (6)
Allied healthcare providers 16.1% (5) 15.4% (8) 24.0% (12) 0 0
Others ‡ 6.5% (2) 1.9% (1) 6.0% (3) 5.6% (1) 11.1% (1) 11.5 12 0.489 *
Medication that might induce MetS
Yes 19.4% (6) 13.5% (7) 12.0% (6) 27.8% (5) 66.7% (6)
No 80.6% (25) 86.5% (45) 88.0% (44) 72.2% (13) 33.3% (3) 16.9 4 0.002 *


















Number of days fruit consumed in
a week ¥ 4.2 ± 2.3 4.3 ± 2.3 4.3 ± 2.3 4.7 ± 2.3 3.8 ± 2.6 0.26 4 0.905
€
Mean (SD) number of servings of
fruit consumed per day ¥ 1.3 ± 0.8 1.3 ± 0.5 1.2 ± 0.6 1 ± 0.4 1.2 ± 0.4 0.93 4 0.448
€
Number of days vegetables
consumed per week ¥ 3.6 ± 1.9 4 ± 2.2 4 ± 2.5 4.9 ± 2.4 4.1 ± 2.8 0.85 4 0.493
€
Number of servings of vegetables
consumed per day ¥ 1.3 ± 0.6 1.4 ± 0.6 1.3 ± 0.5 1.4 ± 0.5 1.4 ± 0.5 0.39 4 0.811
€
Met WHO recommendation for
moderate activity (≥150 min/week)
Yes 88.2% (30) 86.3% (44) 80.0% (40) 88.2% (15) 88.9% (8)
No 11.8% (4) 13.7% (7) 20.0% (10) 11.8% (2) 11.1% (1) 4.67 8 0.792 *
Met WHO recommendation for
vagarious activity (≥75 min/week)
Yes 37.5% (12) 48.0% (24) 46.9% (23) 57.9% (11) 30.0% (3) 5.
No 62.5% (20) 52.0% (26) 53.1% (26) 42.1% (8) 70.0% (7) 70 8 0.680 *
Met WHO criteria for moderate or
vagarious activity
Yes 93.7% (30) 92.3% (48) 86.0% (43) 88.2% (15) 100% (9)
No 6.3% (2) 7.7% (4) 14.0% (7) 11.8% (2) 0 7.81 8 0.452 *
α n = 160 since this only includes participants whose full laboratory workup was available. * Pearson Chi-Square
test. € One-way ANOVA test. ¥ ± represents the standard deviation (SD). † Others included: North Americans,
South Americans, Australians–Oceanians. ‡ Other occupations included: clerk, engineer, IT and aides.
Univariate logistic regression analysis was undertaken to identify the determinants of
MetS. Consuming medications that potentially induce MetS (Such as β blocker, steroids and
anti-psychotics) was associated with a four-fold higher risk of MetS (unadjusted OR 4.4, 95%
CI; 1.74–10.92, p = 0.001). Multiple logistic regression analysis was used to adjust for gender
and physical activities (moderate and vigorous, baseline, and follow-up). Consuming
medications that potentially induce MetS was found to be associated with a six-fold risk of
MetS (AOR 6.3, 95% CI; 2.27–17.73, p < 0.001; Table 7).
Table 7. Logistic regression analysis for factors associated with MetS development at 24-months
post-migration (n = 160) ¥.
Univariate Logistic Regression Multiple Logistic Regression
Unadjusted OR CI p-value Adjusted OR CI p-value
Gender
Male 17.9% (22) 1.4 3
Female 13.5% (5) 1 (reference) (0.48–3.98) 0.534 1 (reference) (0.76–11.85) 0.116
WHO for moderate activities at
baseline met (2017)
Yes 17.5% (25) 2.9 4.4
No 6.7% (1) 1 (reference) (0.37–23.60) 0.285 1 (reference) (0.37–52.74) 0.242
WHO for vigorous activities at
baseline met (2017)
Yes 18.7% (17) 1.5 0.9
No 13.4% (9) 1(reference) (0.62–3.56) 0.379 1 (reference) (0.31–2.87) 0.939
WHO for vigorous activities at
follow-up met (2019)
Yes 17.3% (23) 1.5 (0.40–5.32) 0.561 0.9 (0.21–4.70) 0.996
No 12.5% (3) 1 (reference) 1 (reference)
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Table 7. Cont.
Univariate Logistic Regression Multiple Logistic Regression
WHO for moderate activities at
follow-up met (2019)
Yes 16.4% (12) 0.9 (0.42–2.29) 0.969 1.2 (0.41–3.32) 0.764
No 16.7% (14) 1 (reference) 1 (reference)
Taking medications that induce
MetS
Yes 36.7% (11) 4.4 (1.74–10.92) 0.001 6.3 (2.27–17.73) <0.001
No 11.7% (15) 1 (reference) 1 (reference)
¥ The total number of participants included in the analysis equals 160; however, if there were any single missing
values in the participants’ data, the whole data set related to that participant was excluded.
4. Discussion
Key study findings were that among migrants with normal metabolic parameters at
baseline, 17.0% (95% CI; 11.0–23.0%) developed MetS during their 24-months of residence
in Qatar, with around 81.0% (95% CI; 73.8–86.0%) developing at least one element of MetS—
most commonly central obesity. Administration of medications that potentially induce
MetS increased MetS risk by six-fold.
The incidence of MetS amongst initially MetS-free Qatar migrants rose to 17.0% over
the study period. Van der Linden reported similarly high rates of MetS among Ghanaian
migrants to Europe, compared to their counterparts in Ghana (ranged from 31.4% to 38.4%
vs 8.3%, respectively) [50].
In this study, more than half of the study population developed central obesity during
the study, most likely due to reduced physical activity and a diet with fewer fruit and
vegetable portions—as highlighted in the analysis of the survey data. In a systematic
review of 39 cross-sectional studies, Goulão et al. highlighted the positive association
between obesity prevalence and the length-of-stay in a host country [54,55]. Migration
was associated with weight gain, which directly increased with the duration of migration.
Similar to the findings of the current study, a recent study conducted amongst Qatar
migrants in 2020 also highlighted that male migrants were more likely than females to
develop MetS [41]. Central and South American male migrants to Washington tended
to develop MetS more than female migrants [47]. This variation was attributed to sex
hormones that make men more prone to develop central obesity and subsequent insulin
resistance [56,57].
Regarding sociodemographic parameters, previous studies have shown the MetS-
protective effect of being unmarried (single, divorced or widow), having high education,
occupation levels, and consuming diets rich in fruits and vegetables [58–67]. Other studies
have also highlighted the variation of MetS prevalence between ethnic groups [41,68],
being most marked in South Asian migrants. Conversely, the current study showed no
association between occupation, education, marital status, ethnic origin, and diet with
MetS incidence. However, the limited sample size, the extensive medical background (95%,
n = 195) with similar work environments, and the lack of ethnic variability (81.0% were
Asians) could explain these differences.
Compared to migrants not receiving any medications that alter metabolic parameters,
migrants consuming these medications were at increased risk of MetS by six-fold. The most
commonly reported medications were anti-psychotics, β blockers, steroids, and diuretics.
Several previous studies have confirmed these adverse metabolic effects, with proposed
mechanisms including the promotion of weight gain, fat disposition in the visceral area,
subsequent impaired glucose tolerance, and insulin resistance [69–75]. Caution should
be exercised when prescribing these medications, with periodic monitoring of metabolic
parameters [76].
There are numerous strengths to this study. While all previous studies have focused
on MetS prevalence at one time-point, this is the first study to screen migrants for MetS
at baseline and determine its incidence 24-months post-migration. Hence, the current
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study associates MetS incidence to the migration process itself and subsequent lifestyle
modifications. In addition, this is the first study to assess MetS and its potential determi-
nants amongst migrants to the Middle East and the Gulf. A validated and well-established
questionnaire (WHO STEPwise) was used to address lifestyle modifications [77].
There are limitations to this study; hence, the study findings should be interpreted
with caution. These include the relatively low participation rate, resulting in the study size
being below the calculated sample estimation. There are potential issues of generalisability
beyond the study setting. Notably, most of the population were Asian, and almost all had a
medical background. Baseline questionnaire data may also be subject to recall bias, and
the follow-up period of two years was relatively short. Evidence indicates that a more
extended migration period may be associated with higher MetS prevalence [15].
This study provides evidence on the impact of migration to the Middle East in new-
onset MetS incidence. Assessment and follow-up of these migrants in terms of MetS
and its elements will generally improve health status, control of risk factors, decrease
the likelihood of longer-term consequences and enhance quality of life. This study will
guide policymakers within the Ministry of Public Health and the HMC in implementing
preventative measures to combat MetS among migrants and develop strategies for early
warning systems. Further studies with ethnic and occupational diversity and a more
extended follow-up period are warranted to determine MetS incidence and its determinants
amongst Middle East migrants.
5. Conclusions
There is limited evidence concerning the incidence of MetS and its elements post-
migration, particularly in the Middle East. Migrants to Qatar, particularly males, showed
increased MetS incidence 24-months following migration. Consuming medications that
potentially induce MetS was a significant determinant. These factors should be the subject
of prospective intervention studies.
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